Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioLineRx (BLRX) Liabilities and Shareholders Equity (2023 - 2025)

Historic Liabilities and Shareholders Equity for BioLineRx (BLRX) over the last 3 years, with Q3 2025 value amounting to $39.8 million.

  • BioLineRx's Liabilities and Shareholders Equity fell 2453.07% to $39.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $165.5 million, marking a year-over-year decrease of 2893.38%. This contributed to the annual value of $38.9 million for FY2024, which is 3913.81% down from last year.
  • Per BioLineRx's latest filing, its Liabilities and Shareholders Equity stood at $39.8 million for Q3 2025, which was down 2453.07% from $43.3 million recorded in Q2 2025.
  • BioLineRx's 5-year Liabilities and Shareholders Equity high stood at $68.6 million for Q1 2023, and its period low was $38.9 million during Q4 2024.
  • In the last 3 years, BioLineRx's Liabilities and Shareholders Equity had a median value of $52.7 million in 2024 and averaged $52.6 million.
  • Within the past 5 years, the most significant YoY rise in BioLineRx's Liabilities and Shareholders Equity was 960.36% (2024), while the steepest drop was 3913.81% (2024).
  • Over the past 3 years, BioLineRx's Liabilities and Shareholders Equity (Quarter) stood at $63.9 million in 2023, then crashed by 39.14% to $38.9 million in 2024, then grew by 2.31% to $39.8 million in 2025.
  • Its Liabilities and Shareholders Equity stands at $39.8 million for Q3 2025, versus $43.3 million for Q2 2025 and $43.5 million for Q1 2025.